Literature DB >> 19484788

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

Judd W Moul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19484788     DOI： 10.1002/cncr.24393

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  10 in total

1.  Proven efficacy of combined androgen depletion therapy.

Authors:  Hideyuki Akaza
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

2.  SEOM clinical guidelines for treatment of prostate cancer.

Authors:  José Ángel Arranz Arija; Javier Cassinello Espinosa; Miguel Ángel Climent Durán; Fernando Rivero Herrero
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

3.  Saudi Oncology Society clinical management guidelines for prostate cancer.

Authors:  Ashraf J Abusamra; Shouki Bazarbashi; Yasser Bahader; Hussain Kushi; Danny Rabah; Dany Rabbah; Naser Al Bogami; Khalid Al Ghamdi; Abdullah Al Ghamdi; Khaled Balaraj; Raouf Seyam; Mohammed Al Otaibi; Eyad Al Saeed
Journal:  Urol Ann       Date:  2011-03

4.  Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade.

Authors:  Joon Il Choi; Yun Beom Kim; Seung Ok Yang; Jeong Kee Lee; Tae Young Jung
Journal:  Korean J Urol       Date:  2011-07-24

Review 5.  Hormonal therapy in metastatic prostate cancer: current perspectives and controversies.

Authors:  Manish Garg; Vishwajeet Singh; Manoj Kumar; Satya Narayan Sankhwar
Journal:  Oncol Rev       Date:  2013-09-25

6.  Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors:  Sultan Alkhateeb; Ashraf Abusamra; Danny Rabah; Mohammed Alotaibi; Rana Mahmood; Mubarak Almansour; Esam Murshid; Abdullah Alsharm; Ashwaq Alolayan; Imran Ahmad; Hussain Alkushi; Abdullah Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2014-10

Review 7.  Hormone naïve prostate cancer: predicting and maximizing response intervals.

Authors:  Judd W Moul
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

8.  Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy.

Authors:  Mahmoud Mustafa; Honood Abu Rass; Mothafr Yahya; Khaleel Hamdan; Yazan Eiss
Journal:  World J Surg Oncol       Date:  2021-01-04       Impact factor: 2.754

Review 9.  Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Authors:  Ashraf Abusamra; Esam Murshid; Hussain Kushi; Sultan Alkhateeb; Mubarak Al-Mansour; Ahmad Saadeddin; Danny Rabah; Shouki Bazarbashi; Mohammed Alotaibi; Abdullah Alghamdi; Khalid Alghamdi; Abdullah Alsharm; Imran Ahmad
Journal:  Urol Ann       Date:  2016 Apr-Jun

10.  Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.

Authors:  Satoshi Fukasawa; Hiroyoshi Suzuki; Kazushiro Kawaguchi; Hidehisa Noguchi; Kentaro Enjo; Namphuong Tran; Mary Todd; Karim Fizazi; Nobuaki Matsubara
Journal:  Jpn J Clin Oncol       Date:  2018-11-01       Impact factor: 3.019
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.